Quest for the right Drug

|
עמוד הבית / אוקסיקונטין 80 / מידע מעלון לרופא

אוקסיקונטין 80 OXYCONTIN 80 (OXYCODONE HYDROCHLORIDE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

פומי : PER OS

צורת מינון:

טבליות בשחרור מבוקר : TABLETS CONTROLLED RELEASE

Overdose : מינון יתר

4.9   Overdose

Acute overdose with oxycodone can be manifested by miosis, respiratory depression, hypotension and hallucinations. Circulatory failure and somnolence progressing to stupor or deepening coma, hypotonia, bradycardia, hypoglycemia, pulmonary oedema and death may occur in more severe cases.

Toxic leukoencephalopathy has been observed with oxycodone overdose.

Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.

The effects of overdosage will be potentiated by the simultaneous ingestion of alcohol or other psychotropic drugs.

Treatment of oxycodone overdosage: primary attention should be given to the establishment of a patent airway and institution of assisted or controlled ventilation. The pure opioid antagonists such as naloxone are specific antidotes against symptoms from opioid overdose. Other supportive measures should be employed as needed.

In the case of massive overdosage, administer naloxone intravenously (0.4 to 2 mg for an adult and 0.01 mg/kg body weight for children) if the patient is in a coma or respiratory depression is present.
Repeat the dose at 2 minute intervals if there is no response. If repeated doses are required an infusion of 60% of the initial dose per hour is a useful starting point. A solution of 10 mg made up in 50 ml dextrose will produce 200 micrograms/ml for infusion using an IV pump (dose adjusted to the clinical response). Infusions are not a substitute for frequent review of the patient’s clinical state. Intramuscular naloxone is an alternative in the event that IV access is not possible. As the duration of action of naloxone is relatively short, the patient must be carefully monitored until spontaneous respiration is reliably re-established. Naloxone is a competitive antagonist and large doses (4 mg) may be required in seriously poisoned patients.

For less severe overdosage, administer naloxone 0.2 mg intravenously followed by increments of 0.1 mg every 2 minutes if required.

The patient should be observed for at least 6 hours after the last dose of naloxone.

Naloxone should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to oxycodone overdosage. Naloxone should be administered cautiously to persons who are known, or suspected, to be physically dependent on oxycodone. In such cases, an abrupt or complete reversal of opioid effects may precipitate pain and an acute withdrawal syndrome.


Additional/other considerations:
• Consider activated charcoal (50 g for adults, 10 -15 g for children), if a substantial amount has been ingested within 1 hour, provided the airway can be protected. It may be reasonable to assume that late administration of activated charcoal may be beneficial for prolonged release preparations; however, there is no evidence to support this.

•   OxyContin tablets will continue to release and add to the oxycodone load for up to 12 hours after administration and the management of oxycodone overdosage should be modified accordingly. Gastric contents may therefore need to be emptied as this can be useful in removing unabsorbed drug, particularly when a prolonged release formulation has been taken.


שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל 01/01/2000
הגבלות תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת

בעל רישום

RAFA LABORATORIES LTD

רישום

108 98 29256 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

12.04.21 - עלון לרופא 02.11.22 - עלון לרופא 05.12.22 - עלון לרופא 25.08.23 - עלון לרופא 03.06.24 - עלון לרופא 05.09.24 - עלון לרופא

עלון מידע לצרכן

14.02.13 - עלון לצרכן 06.08.15 - עלון לצרכן אנגלית 01.08.21 - עלון לצרכן אנגלית 01.08.21 - עלון לצרכן עברית 01.08.21 - עלון לצרכן ערבית 02.11.22 - עלון לצרכן עברית 11.05.23 - עלון לצרכן אנגלית 11.05.23 - עלון לצרכן עברית 11.05.23 - עלון לצרכן ערבית 01.08.23 - עלון לצרכן אנגלית 01.08.23 - עלון לצרכן עברית 01.08.23 - עלון לצרכן ערבית 03.06.24 - עלון לצרכן עברית 05.09.24 - עלון לצרכן עברית 05.03.19 - החמרה לעלון 12.04.21 - החמרה לעלון 27.05.13 - החמרה לעלון 02.11.22 - החמרה לעלון 05.12.22 - החמרה לעלון 07.09.23 - החמרה לעלון 06.06.24 - החמרה לעלון 05.09.24 - החמרה לעלון

לתרופה במאגר משרד הבריאות

אוקסיקונטין 80

קישורים נוספים

RxList WebMD Drugs.com